Adjuvant therapy in completely resected non-small-cell lung cancer.


Less than 20% to 25% of patients with non-small-cell lung cancer (NSCLC) present with stage I or II disease and are best treated by surgical resection. Long-term survival in early NSCLC remains poor. The 5-year survival rate of patients who undergo complete surgical resection is only 40% to 50%. The majority of relapses after surgery are distant metastases… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics